 Well, good afternoon, everyone. I want to thank, first off, Dr. Minolio, for the very kind invitation to our office. I want to thank NIH as well for convening this very important meeting. I bring greetings from the Assistant Secretary for Health, Dr. Howard Koh, who wanted to be here but couldn't be here today, but sends his regards. Obviously, this is a critical, critical area, the integration of genomics with clinical medicine, cutting edge area that'll only grow more and more important. I also want to introduce a colleague of mine, Dr. Lisa Lee, who's here with me today, and you'll be hearing from Lisa in just a couple of minutes. She is the Executive Director of the Presidential Commission for the Study of Bioethical Issues. They've tackled issues related to genomic medicine, and Lisa's going to talk a little bit about their work in a couple of minutes, and that commission is housed within the Assistant Secretary for Health's office as well. I think many of you who are a part of Health and Human Services know about the mission of the Assistant Secretary for Health's office, but just to review, the responsibility is broad. It's to help the Secretary of Health and Human Services in the department and provide leadership in ensuring coordination and collaboration on key public health issues. So we're broad, actually very broad. We have 12 public health offices in a variety of areas, so we have offices focusing on subsets of the population, office on minority health, women's health, adolescent health, family planning. We have offices that focus on key public health issues, whether it's vaccines or disease prevention, HIV, AIDS, blood safety. We do have a few regulatory offices, the Office for Human Research Protections, whose director, Dr. J. Menikoff, actually wanted to be here today, but just got pulled off to a last minute meeting. We have an office on research integrity as well. The certain general's office is within our office. So again, quite broad in terms of our responsibility, 12 public health offices. We also have 10 presidential or secretarial advisory committees, and Dr. Lee's commission is one of those 10. We're currently doing a scan of our office in terms of trying to understand who is working in the areas of genomic medicine, and I think that will be quite revealing. Obviously, Lisa's work and Jerry's work does touch on that interface, but I did want to just touch on, in the couple of minutes I had, on one substantive area that's being led through our Office on Disease Prevention and Health Promotion. Many of you have heard of Healthy People, I hope. Healthy People are the nation's health objectives first set out in 1979. Every decade, there are new set of health objectives. Healthy People 2020 was issued in the latter stage of 2010. And again, these are hundreds of objectives, the nation's health objectives, which we track over time to see if we're making progress. There are actually 42 topic areas for which these objectives are categorized, and actually one of the new topic areas in Healthy People 2020 is genomic medicine. This is led by CDC. You'll hear from Dr. Query in a few minutes. It's also co-led by ARC you've heard from Dr. Clancy. So genomic medicine is a new topic area. The goal is to improve health and prevent harm through valid and useful genomic tools in clinical and public health practice. There are actually two now objectives in Healthy People 2020 related to genomics. One is actually, it's actually one, one in practice and one in development. And they stem from recommendations made from independent panels on genetic testing based on thorough review of the scientific evidence. And I just wanna run through both of these recommendations so you know these objectives that we're following. They're both in the area of cancer prevention. The first recommendation is from the US Preventive Service Task Force. It's a recommendation focused on women who have a high-risk family history pattern for breast and ovarian cancer who could benefit from receiving genetic counseling to learn about genetic testing for BRCA one or two mutations. Given that recommendation from the task force, there is an objective in Healthy People, which is to increase the proportion of women with a family history of breast and ovarian cancer who receive genetic counseling. Now in 2005, based on data from the National Health Interview Survey with CDC tracks, about 35% of women with a family history of breast and or ovarian cancer received genetic counseling. That's in 2005, in 2010 that number jumped to about 53%. So in tremendous progress in those five years and you can imagine this will continue to track upwards given that this is also an A or B recommendation of the US Preventive Service Task Force. There are implications here because of the Affordable Care Act and the waiving of cost sharing for recommended services. So this is certainly an area that we are following through Healthy People. The second recommendation actually comes from the Evaluation of Genomic Applications in Practice and Prevention Working Group. This is a recommendation related to colorectal cancer screening. The idea that those newly diagnosed with colorectal cancer should receive counseling and educational materials about genetic testing to seek individuals who might actually have a hereditary predisposition of colorectal cancer. This is Lynch syndrome for many of you who are familiar with this. So there is a developmental, I think it's still developmental, a developmental objective to increase the proportion of persons with newly diagnosed colorectal cancer who receive genetic testing to identify a Lynch syndrome and this is being tracked again through CDC and NIH data. So again, those are just two examples of really, I think, cutting edge over the last few years applications of using genomics that are being used, certainly at least for BRCA, by frontline providers that we're now tracking from a population health perspective through Healthy People. We realize this is an important area. The future of medicine will continue to fully embrace genomic medicine. So I think that's very exciting. I'm gonna just stop here. I'm gonna ask Dr. Lee to offer some additional thoughts as well as to discuss how her office's specific efforts interface with genomic medicine, just so you have a broader understanding of OASH's work and how we link to this topic. Lisa? Thank you.